Canada markets open in 19 minutes
  • S&P/TSX

    18,441.84
    -207.08 (-1.11%)
     
  • S&P 500

    3,640.47
    -78.57 (-2.11%)
     
  • DOW

    29,225.61
    -458.13 (-1.54%)
     
  • CAD/USD

    0.7279
    -0.0031 (-0.43%)
     
  • CRUDE OIL

    81.06
    -0.17 (-0.21%)
     
  • BTC-CAD

    26,483.95
    -123.43 (-0.46%)
     
  • CMC Crypto 200

    440.94
    -5.04 (-1.13%)
     
  • GOLD FUTURES

    1,673.10
    +4.50 (+0.27%)
     
  • RUSSELL 2000

    1,674.93
    -40.31 (-2.35%)
     
  • 10-Yr Bond

    3.7080
    -0.0390 (-1.04%)
     
  • NASDAQ futures

    11,236.75
    +8.50 (+0.08%)
     
  • VOLATILITY

    31.36
    +1.18 (+3.91%)
     
  • FTSE

    6,887.06
    +5.47 (+0.08%)
     
  • NIKKEI 225

    25,937.21
    -484.84 (-1.83%)
     
  • CAD/EUR

    0.7462
    +0.0020 (+0.27%)
     

Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference

·1 min read
Generation Bio Co.
Generation Bio Co.

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit www.generationbio.com.

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638